BriaCell Therapeutics Statistics
Total Valuation
BCTX has a market cap or net worth of $14.44 million. The enterprise value is $13.51 million.
| Market Cap | 14.44M |
| Enterprise Value | 13.51M |
Important Dates
The last earnings date was Friday, June 14, 2024, after market close.
| Earnings Date | Jun 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BCTX has 18.28 million shares outstanding. The number of shares has increased by 2.99% in one year.
| Shares Outstanding | 18.28M |
| Shares Change (YoY) | +2.99% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 15.56% |
| Owned by Institutions (%) | 12.04% |
| Float | 13.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.82
| Current Ratio | 0.82 |
| Quick Ratio | 0.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 1.41 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -37.60% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$377,204 |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.66% in the last 52 weeks. The beta is 1.91, so BCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.91 |
| 52-Week Price Change | -87.66% |
| 50-Day Moving Average | 1.34 |
| 200-Day Moving Average | 3.26 |
| Relative Strength Index (RSI) | 32.10 |
| Average Volume (20 Days) | 802,390 |
Short Selling Information
The latest short interest is 563,334, so 3.08% of the outstanding shares have been sold short.
| Short Interest | 563,334 |
| Short Previous Month | 628,314 |
| Short % of Shares Out | 3.08% |
| Short % of Float | 4.32% |
| Short Ratio (days to cover) | 4.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.27M |
| Pretax Income | -6.04M |
| Net Income | -6.04M |
| EBITDA | -20.78M |
| EBIT | -20.80M |
| Earnings Per Share (EPS) | -$1.25 |
Balance Sheet
The company has $935,694 in cash and no debt, giving a net cash position of $935,694 or $0.05 per share.
| Cash & Cash Equivalents | 935,694 |
| Total Debt | n/a |
| Net Cash | 935,694 |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | -5.97M |
| Book Value Per Share | -0.33 |
| Working Capital | -1.23M |
Cash Flow
| Operating Cash Flow | -31.01M |
| Capital Expenditures | n/a |
| Free Cash Flow | -31.01M |
| FCF Per Share | -$1.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.99% |
| Shareholder Yield | -2.99% |
| Earnings Yield | -41.78% |
| FCF Yield | -214.67% |
Analyst Forecast
The average price target for BCTX is $18.00, which is 2,178.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.00 |
| Price Target Difference | 2,178.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 2, 2020. It was a reverse split with a ratio of 1:300.
| Last Split Date | Jan 2, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:300 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |